Kalaris Therapeutics annual r&d spending
2019
2020
2021
2022
2023
2024
2025
Kalaris Therapeutics R&D Spending Growth & History (KLRS)
Kalaris Therapeutics's r&d spending was $30.8M for fiscal 2025.
View full Kalaris Therapeutics company overviewKalaris Therapeutics annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $30.8M | −$14.3M | −31.72% |
| 2024 | 2024-12-31 | $45.0M | −$88.0M | −66.15% |
| 2023 | 2023-12-31 | $133.1M | $14.2M | +11.95% |
| 2022 | 2022-12-31 | $118.9M | −$1.9M | −1.54% |
| 2021 | 2021-12-31 | $120.7M | $71.1M | +143.11% |
| 2020 | 2020-12-31 | $49.7M | $33.4M | +205.66% |
| 2019 | 2019-12-31 | $16.2M | — | — |
Kalaris Therapeutics quarterly r&d spending
Q2.19
Q3.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $9.0M | $578,000 | +6.85% |
| Q1 2026 | 2026-03-31 | $7.6M | $1.5M | +25.57% |
| Q4 2025 | 2025-12-31 | $7.2M | $3.3M | +85.90% |
| Q3 2025 | 2025-09-30 | $9.1M | −$26.9M | −74.66% |
| Q2 2025 | 2025-06-30 | $8.4M | $5.2M | +162.85% |
| Q1 2025 | 2025-03-31 | $6.0M | $4.1M | +207.50% |
| Q4 2024 | 2024-12-31 | $3.9M | −$29.5M | −88.46% |
| Q3 2024 | 2024-09-30 | $36.0M | $1.9M | +5.46% |
| Q2 2024 | 2024-06-30 | $3.2M | −$31.6M | −90.78% |
| Q1 2024 | 2024-03-31 | $2.0M | −$28.8M | −93.62% |
| Q4 2023 | 2023-12-31 | $33.4M | $5.0M | +17.42% |
| Q3 2023 | 2023-09-30 | $34.2M | $4.2M | +13.84% |
| Q2 2023 | 2023-06-30 | $34.8M | $3.4M | +10.98% |
| Q1 2023 | 2023-03-31 | $30.7M | $1.7M | +5.68% |
| Q4 2022 | 2022-12-31 | $28.4M | −$13.2M | −31.69% |
| Q3 2022 | 2022-09-30 | $30.0M | −$3.1M | −9.25% |
| Q2 2022 | 2022-06-30 | $31.4M | $5.7M | +22.21% |
| Q1 2022 | 2022-03-31 | $29.1M | $8.7M | +42.53% |
| Q4 2021 | 2021-12-31 | $41.6M | $24.8M | +148.27% |
| Q3 2021 | 2021-09-30 | $33.1M | $15.9M | +92.42% |
| Q2 2021 | 2021-06-30 | $25.7M | $16.8M | +188.99% |
| Q1 2021 | 2021-03-31 | $20.4M | $13.6M | +198.19% |
| Q4 2020 | 2020-12-31 | $16.8M | — | — |
| Q3 2020 | 2020-09-30 | $17.2M | $11.5M | +203.84% |
| Q2 2020 | 2020-06-30 | $8.9M | $6.1M | +222.50% |
| Q1 2020 | 2020-03-31 | $6.8M | — | — |
| Q3 2019 | 2019-09-30 | $5.7M | — | — |
| Q2 2019 | 2019-06-30 | $2.8M | — | — |
Kalaris Therapeutics r&d spending trends
Over the last five fiscal years, Kalaris Therapeutics's r&d spending decreased from $49.7M to $30.8M, a change of −$18.9M. The latest reported quarter, Q2 2026, shows $9.0M.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Kalaris Therapeutics source filings ↗